Raymond James analyst Reni Benjamin maintained a Hold rating on Audentes Therapeutics (NASDAQ: BOLD) yesterday. The company’s shares closed yesterday at $33.65.
Benjamin commented:
“We are maintaining our Market Perform rating on BOLD. Wednesday, after market close, Audentes reported 1Q18 financial results and provided an update on their gene therapy programs.”
According to TipRanks.com, Benjamin is a 3-star analyst with an average return of 2.4% and a 44.5% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Invivo Therapeutics Holdings, Adaptimmune Therapeutics, and Bellicum Pharmaceuticals.
Currently, the analyst consensus on Audentes Therapeutics is Moderate Buy and the average price target is $31.50, representing a -6.4% downside.
In a report released yesterday, Mizuho Securities also maintained a Hold rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.80 and a one-year low of $13.90. Currently, Audentes Therapeutics has an average volume of 329.7K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
